Becton, Dickinson and Company $BDX Stock: Sumitomo Mitsui DS Asset Management Company Ltd Grows Holdings

Key Points

• Sumitomo Mitsui DS Asset Management increased its BDX stake by 18.9% in the third quarter, bringing its holdings to 43,413 shares worth approximately $7.8 million. Institutional investors and hedge funds collectively own 86.97% of the company.
• Becton Dickinson reported quarterly revenue of $4.98 billion and adjusted earnings of $3.23 per share, exceeding analyst estimates, while revenue rose 5.4% year over year. The company guided to fiscal 2026 EPS of $12.62–$12.72.
• BDX shares traded near a one-year high at $194.29, while analysts maintained a mixed outlook with an average rating of “Hold” and an average price target of $185.07. The company also pays a quarterly dividend of $1.05, equivalent to a 2.2% yield.

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,413 shares of the medical instruments supplier's stock after purchasing an additional 6,887 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Becton, Dickinson and Company were worth $7,771,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of BDX. Maryland Capital Advisors Inc. lifted its holdings in shares of Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 139 shares during the period. SHP Wealth Management bought a new position in Becton, Dickinson and Company during the fourth quarter valued at about $26,000. Meeder Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 102 shares in the last quarter. Main Street Group LTD acquired a new position in Becton, Dickinson and Company during the first quarter worth about $29,000. Finally, Bell Investment Advisors Inc acquired a new position in Becton, Dickinson and Company during the second quarter worth about $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 0.3%

Shares of BDX opened at $194.29 on Thursday. The business's 50-day moving average price is $184.73 and its 200 day moving average price is $164.54. The stock has a market capitalization of $53.53 billion, a P/E ratio of 58.52, a P/E/G ratio of 13.07 and a beta of 0.21. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $195.99. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the company earned $3.68 EPS. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insider Activity

In other news, EVP Michael Feld sold 165 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,906 shares of company stock worth $1,265,855 over the last 90 days. 0.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target on the stock. Wolfe Research assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday. They set an "outperform" rating for the company. Jefferies Financial Group reaffirmed a "buy" rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an "underweight" rating and a $165.00 price objective on the stock. Finally, Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.